APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceuticals in Nuclear Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchRadiopharmaceuticals in Nuclear Medicine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceuticals in Nuclear Medicine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Radiopharmaceuticals in Nuclear Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiopharmaceuticals in Nuclear Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiopharmaceuticals in Nuclear Medicine market include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Radiopharmaceuticals in Nuclear Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceuticals in Nuclear Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceuticals in Nuclear Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

Mundipharma

Novartis

SIEMENS

Bayer

Dongcheng

Eli Lilly

China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals

Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology

Cardiology

Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Radiopharmaceuticals in Nuclear Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Radiopharmaceuticals in Nuclear Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiopharmaceuticals in Nuclear Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Radiopharmaceuticals in Nuclear Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceuticals in Nuclear Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceuticals in Nuclear Medicine industry.

Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Radiopharmaceuticals in Nuclear Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceuticals in Nuclear Medicine Industry Trends Table 2. Radiopharmaceuticals in Nuclear Medicine Industry Drivers Table 3. Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges Table 4. Radiopharmaceuticals in Nuclear Medicine Industry Restraints Table 5. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Company (2021-2026) Table 7. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Radiopharmaceuticals in Nuclear Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Radiopharmaceuticals in Nuclear Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Radiopharmaceuticals in Nuclear Medicine Company, Product Type & Application Table 13. Global Radiopharmaceuticals in Nuclear Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiopharmaceuticals in Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diagnostic Radiopharmaceuticals Table 18. Significant Companies of Therapy Radiopharmaceuticals Table 19. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Type (2021-2026) Table 23. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Type (2027-2032) Table 24. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type (2021-2026) Table 28. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oncology Table 30. Significant Companies of Cardiology Table 31. Significant Companies of Other Table 32. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Application (2021-2026) Table 36. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Application (2027-2032) Table 37. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application (2021-2026) Table 41. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application (2027-2032) Table 42. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026) & (K Units) Table 44. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2026) Table 45. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2027-2032) & (K Units) Table 46. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2027-2032) Table 47. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Region (2021-2026) Table 50. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Region (2027-2032) Table 52. Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Radiopharmaceuticals in Nuclear Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 57. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2026) Table 58. Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 59. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2027-2032) Table 60. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Market Share by Country (2021-2026) Table 62. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Market Share by Country (2027-2032) Table 64. Aurobindo Pharma Company Information Table 65. Aurobindo Pharma Business Overview Table 66. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 68. Aurobindo Pharma Recent Development Table 69. Bracco Imaging Company Information Table 70. Bracco Imaging Business Overview Table 71. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 73. Bracco Imaging Recent Development Table 74. Cardinal Health Company Information Table 75. Cardinal Health Business Overview Table 76. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 78. Cardinal Health Recent Development Table 79. Curium Pharma Company Information Table 80. Curium Pharma Business Overview Table 81. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 83. Curium Pharma Recent Development Table 84. GE Healthcare Company Information Table 85. GE Healthcare Business Overview Table 86. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 88. GE Healthcare Recent Development Table 89. Jubilant Pharma Company Information Table 90. Jubilant Pharma Business Overview Table 91. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 93. Jubilant Pharma Recent Development Table 94. Lantheus Company Information Table 95. Lantheus Business Overview Table 96. Lantheus Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 98. Lantheus Recent Development Table 99. Mundipharma Company Information Table 100. Mundipharma Business Overview Table 101. Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 103. Mundipharma Recent Development Table 104. Novartis Company Information Table 105. Novartis Business Overview Table 106. Novartis Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 108. Novartis Recent Development Table 109. SIEMENS Company Information Table 110. SIEMENS Business Overview Table 111. SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 113. SIEMENS Recent Development Table 114. Bayer Company Information Table 115. Bayer Business Overview Table 116. Bayer Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 118. Bayer Recent Development Table 119. Dongcheng Company Information Table 120. Dongcheng Business Overview Table 121. Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 123. Dongcheng Recent Development Table 124. Eli Lilly Company Information Table 125. Eli Lilly Business Overview Table 126. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 128. Eli Lilly Recent Development Table 129. China Isotope & Radiation Company Information Table 130. China Isotope & Radiation Business Overview Table 131. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 133. China Isotope & Radiation Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Radiopharmaceuticals in Nuclear Medicine Distributors List Table 137. Radiopharmaceuticals in Nuclear Medicine Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Radiopharmaceuticals in Nuclear Medicine Product Image Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceuticals in Nuclear Medicine Sales (2021-2032) & (K Units) Figure 5. Global Radiopharmaceuticals in Nuclear Medicine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diagnostic Radiopharmaceuticals Image Figure 10. Therapy Radiopharmaceuticals Image Figure 11. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Type (2021-2032) Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type (2021-2032) Figure 17. Oncology Image Figure 18. Cardiology Image Figure 19. Other Image Figure 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Application (2021-2032) Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application (2021-2032) Figure 26. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Radiopharmaceuticals in Nuclear Medicine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Radiopharmaceuticals in Nuclear Medicine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic Radiopharmaceuticals
  • Therapy Radiopharmaceuticals
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Aurobindo Pharma
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • Mundipharma
  • Novartis
  • SIEMENS
  • Bayer
  • Dongcheng
  • Eli Lilly
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
  1. 2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
  2. 2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
  3. 2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Radiopharmaceuticals in Nuclear Medicine Market by Company
  1. 3.1 Global Radiopharmaceuticals in Nuclear Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Radiopharmaceuticals in Nuclear Medicine Company Ranking (2024-2026)
  6. 3.6 Global Radiopharmaceuticals in Nuclear Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Radiopharmaceuticals in Nuclear Medicine Company Product Type and Application
  8. 3.8 Global Radiopharmaceuticals in Nuclear Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceuticals in Nuclear Medicine Market by Type
  1. 4.1 Radiopharmaceuticals in Nuclear Medicine Type Introduction
  2. 4.1.1 Diagnostic Radiopharmaceuticals
  3. 4.1.2 Therapy Radiopharmaceuticals
  4. 4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type
  5. 4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type
  9. 4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type (2021-2032)
5 Radiopharmaceuticals in Nuclear Medicine Market by Application
  1. 5.1 Radiopharmaceuticals in Nuclear Medicine Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application
  6. 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application
  10. 5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application (2021-2032)
6 Radiopharmaceuticals in Nuclear Medicine Regional Sales and Value Analysis
  1. 6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2027-2032)
  5. 6.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Radiopharmaceuticals in Nuclear Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceuticals in Nuclear Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032)
  6. 7.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Radiopharmaceuticals in Nuclear Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 Bracco Imaging
  8. 8.2.1 Bracco Imaging Company Information
  9. 8.2.2 Bracco Imaging Business Overview
  10. 8.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  12. 8.2.5 Bracco Imaging Recent Developments
  13. 8.3 Cardinal Health
  14. 8.3.1 Cardinal Health Company Information
  15. 8.3.2 Cardinal Health Business Overview
  16. 8.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  18. 8.3.5 Cardinal Health Recent Developments
  19. 8.4 Curium Pharma
  20. 8.4.1 Curium Pharma Company Information
  21. 8.4.2 Curium Pharma Business Overview
  22. 8.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  24. 8.4.5 Curium Pharma Recent Developments
  25. 8.5 GE Healthcare
  26. 8.5.1 GE Healthcare Company Information
  27. 8.5.2 GE Healthcare Business Overview
  28. 8.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  30. 8.5.5 GE Healthcare Recent Developments
  31. 8.6 Jubilant Pharma
  32. 8.6.1 Jubilant Pharma Company Information
  33. 8.6.2 Jubilant Pharma Business Overview
  34. 8.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  36. 8.6.5 Jubilant Pharma Recent Developments
  37. 8.7 Lantheus
  38. 8.7.1 Lantheus Company Information
  39. 8.7.2 Lantheus Business Overview
  40. 8.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  42. 8.7.5 Lantheus Recent Developments
  43. 8.8 Mundipharma
  44. 8.8.1 Mundipharma Company Information
  45. 8.8.2 Mundipharma Business Overview
  46. 8.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  48. 8.8.5 Mundipharma Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 SIEMENS
  56. 8.10.1 SIEMENS Company Information
  57. 8.10.2 SIEMENS Business Overview
  58. 8.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  60. 8.10.5 SIEMENS Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Dongcheng
  68. 8.12.1 Dongcheng Company Information
  69. 8.12.2 Dongcheng Business Overview
  70. 8.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  72. 8.12.5 Dongcheng Recent Developments
  73. 8.13 Eli Lilly
  74. 8.13.1 Eli Lilly Company Information
  75. 8.13.2 Eli Lilly Business Overview
  76. 8.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  78. 8.13.5 Eli Lilly Recent Developments
  79. 8.14 China Isotope & Radiation
  80. 8.14.1 China Isotope & Radiation Company Information
  81. 8.14.2 China Isotope & Radiation Business Overview
  82. 8.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  84. 8.14.5 China Isotope & Radiation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
  2. 9.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiopharmaceuticals in Nuclear Medicine Sales Mode & Process
  6. 9.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
  9. 9.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst